Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)

臺大醫院;臺大醫院-腫瘤醫學部;臺大醫學院-腫瘤醫學研究所;Passaro, A.A.PassaroYang, J. C.J. C.YangAhn, M.M.AhnDickgreber, N. J.N. J.DickgreberHalmos, B.B.HalmosHirsh, V.V.HirshHochmair, M. J.M. J.HochmairLevy, B. P.B. P.Levyde Marinis, F.F.de MarinisMok, T.T.MokO'Byrne, K.K.O'ByrneOkamoto, I.I.OkamotoSchuler, M.M.SchulerSebastian, M.M.SebastianShah, R.R.ShahTan, E.E.TanYamamoto, N.N.YamamotoMaerten, A.A.MaertenWind, S.S.WindCarbone, D. P.D. P.Carbone2017-06-272018-07-092017-06-272018-07-092015http://ntur.lib.ntu.edu.tw//handle/246246/280155[SDGs]SDG3Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)